New blood processing method could cut transfusion needs for sickle cell patients
NCT ID NCT06743113
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether red blood cells processed to be low in oxygen (hypoxic) last longer in the body than standard cells for people with sickle cell anemia who need regular transfusions. About 48 participants aged 7 and older will receive both types of blood in a crossover design. The goal is to see if hypoxic cells slow the drop in healthy hemoglobin levels, potentially reducing how often transfusions are needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hypoxic red blood cells processed with the Hemanext ONE system
What this could lead to
If it works, this could reduce how often patients with sickle cell anemia need transfusions, easing treatment burden.
What could go wrong
This is a small early-stage trial with only 48 participants, so results may not apply to everyone. The device is new, and long-term benefits or risks are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL ANEMIA IN CHILDREN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
John Hopkins University School of Medicine
Baltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, 33701, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
New England Sickle Cell Institute, University of Connecticut
Farmington, Connecticut, 06030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15260, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact